Keyphrases
5-fluorouracil (5-FU)
8%
Adult T-cell Leukemia
36%
Advanced Solid Tumors
13%
AIDS/HIV
19%
Amino Acids
11%
Androgen Receptor
12%
Apoptosis
12%
Bone Marrow
10%
Bone Metastasis
16%
Breast Cancer
34%
Breast Cancer Patients
16%
C-X-C Chemokine Receptor Type 4 (CXCR4)
8%
Cancer Patients
12%
Chemotherapy
32%
Clear Cell Renal Cell Carcinoma (ccRCC)
47%
Clinical Outcomes
13%
Clinical Trials
15%
Co-receptor
9%
Confidence Interval
16%
Dose Escalation
9%
Dose-limiting Toxicity
9%
Envelope Protein
10%
ErbB2
9%
Estrogen Receptor 1 (ESR1)
12%
Everolimus
8%
Gemcitabine
17%
Gene Expression
16%
Genetic Modification
12%
Gp120
8%
Heat Shock Protein 90 (Hsp90)
9%
HIV-2
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
26%
Human Immunodeficiency Virus Type 1 (HIV-1)
83%
Human T-cell Leukemia Virus Type 1 (HTLV-1)
100%
Immortalization
9%
In Cancer
19%
Infected Cells
10%
Infectivity
10%
Integrin
18%
Interferon-α (IFN-α)
16%
Kidney Cancer
14%
Lymphoma
11%
Macrophages
16%
Malignancy
18%
Mass Spectrometry
8%
Median Overall Survival
8%
Melanoma
11%
Metastasis
13%
Metastatic Breast Cancer
19%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
9%
Metastatic Disease
11%
Metastatic Pancreatic Cancer
15%
Metastatic Pancreatic Ductal Adenocarcinoma
14%
Metastatic Renal Cell Carcinoma (mRCC)
20%
Microphthalmia-associated Transcription Factor
9%
Monotherapy
9%
Mouse Model
15%
Neoadjuvant
8%
Neratinib
12%
NF-B
15%
Oncogene
17%
Oncoprotein
8%
Osteoclast
13%
Overall Survival
28%
Overexpression
10%
Pancreatic Cancer
33%
Pancreatic Ductal Adenocarcinoma
25%
Partial Response
8%
Patient-derived Xenograft
26%
Phase II Study
8%
Phase II Trial
14%
Phosphorylation
25%
Poor Prognosis
11%
Progression-free Survival
13%
Prostate Cancer
16%
Randomized Phase II Trial
9%
Renal Cell Carcinoma
26%
Retrovirus
12%
Solid Tumors
9%
Somatic mutation
10%
T Cells
39%
Targeted Therapy
15%
Therapeutic Potential
8%
Transgenic Mice
9%
Trastuzumab
17%
Triple-negative Breast Cancer
21%
Tropics
8%
Tumor
80%
Tumor Cells
17%
Tumor Growth
27%
Tumor Microenvironment
12%
Tumor Subtype
9%
Tumor Suppressor
9%
Tumorigenesis
21%
Upstream Open Reading Frame (uORF)
11%
V3 Loop
12%
Viral
10%
Virus
31%
Virus Type
9%
Zoledronic Acid
9%
Medicine and Dentistry
Adult T-Cell Leukemia/Lymphoma
27%
Adverse Event
11%
Androgen Receptor
8%
Arm
15%
B Cell
5%
Biological Marker
17%
Bladder Cancer
5%
Bone Cancer
7%
Bone Metastasis
15%
Breast Cancer
48%
Cancer
30%
Cancer Cell
7%
Cancer Therapy
7%
Carcinogenesis
11%
Castration Resistant Prostate Cancer
7%
Cell Death
5%
Cell Line
8%
Chemoradiotherapy
5%
Clear Cell
5%
Clear Cell Renal Cell Carcinoma
54%
Clinical Trial
21%
Diagnosis
5%
Diseases
36%
Drive
6%
Epidermal Growth Factor Receptor
5%
Epidermal Growth Factor Receptor 2
5%
Everolimus
7%
Fluorouracil
5%
Gemcitabine
10%
Gene Expression
5%
Hodgkin's Lymphoma
5%
Hormone Therapy
11%
Human Immunodeficiency Virus
20%
Human Immunodeficiency Virus 1
7%
Human T Cell Leukemia Virus
8%
Human T-Lymphotropic Virus 1
30%
Immune Checkpoint Inhibitor
5%
Immunity
7%
Immunotherapy
13%
In Vitro
8%
Integrin
12%
Interferon
7%
Kidney Cancer
13%
Kidney Metastasis
11%
Leukemia
9%
Lymphocyte
6%
Macrophage
8%
Magnetic Resonance Imaging
5%
Malignant Neoplasm
43%
Melanoma
12%
Metastatic Breast Cancer
13%
Metastatic Carcinoma
32%
Microphthalmia Associated Transcription Factor
8%
Multiple Myeloma
8%
Neoadjuvant Chemotherapy
6%
Neoplasm
98%
Neratinib
6%
Non-Hodgkin Lymphoma
6%
Oncogene
6%
Oncology
6%
Oncoprotein
5%
Osteoclast
10%
Osteolysis
10%
Overall Survival
28%
Paclitaxel
5%
Pancreas Adenocarcinoma
32%
Pancreas Cancer
36%
Phase II Trials
8%
Positron Emission Tomography
7%
Primary Tumor
7%
Programmed Cell Death
10%
Progression Free Survival
14%
Promoter Region
5%
Prostate Cancer
19%
Protein P53
5%
Proteomics
7%
Radiation Therapy
11%
Recurrent Disease
8%
Solid Malignant Neoplasm
7%
Somatic Mutation
6%
Stem Cell
5%
Surgery
7%
Systemic Therapy
6%
T Cell
21%
T Lymphocyte Receptor
5%
Targeted Therapy
18%
Transgenic Mouse
9%
Trastuzumab
12%
Triple Negative Breast Cancer
11%
Tumor Cell
11%
Tumor Microenvironment
6%
Tumor Progression
26%
Tumor Xenograft
7%
Tyrosine-Kinase Inhibitor
5%
Vasculotropin
5%
Virus
5%
Xenograft
18%
Zoledronic Acid
7%